α7-烟碱型乙酰胆碱受体激动剂VQW-765治疗表演焦虑的疗效与安全性:随机双盲安慰剂对照试验
这项随机双盲安慰剂对照试验纳入230名有公开演讲焦虑史的成人,单次口服10 mg VQW-765(n=116)或安慰剂(n=114)后接受Trier社会应激测试。VQW-765在表演阶段对焦虑强度的改善仅呈趋势(P=0.1443),女性应答更显著(P=0.034),中间50%血药浓度分位者SUDS评分显著改善(P=0.033)且仅见于女性(P=0.005)。VQW-765安全且耐受良好。
要点
- VQW-765对表演焦虑的总体改善未达统计学显著,仅呈趋势。
- 女性对VQW-765的应答幅度更大且显著。
- 中间50%血药浓度分位者焦虑改善显著,但仅限女性。
核心结论
- 这是首个显示α7-nAChR激动剂在人体具有抗焦虑效应的研究。
- VQW-765是有望开发用于社交焦虑障碍按需治疗的新药候选。
研究设计与样本
- 随机、双盲、安慰剂对照试验,纳入230名有公开演讲焦虑史的成人。
- 参与者随机接受单次口服10 mg VQW-765(n=116)或安慰剂(n=114),随后进行Trier社会应激测试(TSST)。
- 采用主观痛苦单位量表(SUDS)评估焦虑水平,TSST期间监测心率,TSST后测定VQW-765血浆浓度。
主要发现
- VQW-765组在TSST表演阶段的SUDS焦虑强度较安慰剂组呈改善趋势(P=0.1443)。
- 女性对VQW-765的应答幅度更大且显著(P=0.034)。
- 药代动力学/药效学分析观察到倒U型暴露-效应关系。
- VQW-765血浆浓度中间50%分位者SUDS评分较安慰剂显著改善(P=0.033),但亚组分析显示仅见于女性(P=0.005)。
- VQW-765安全且耐受良好。
关键数值与推荐
- VQW-765组与安慰剂组在TSST表演阶段SUDS改善比较P=0.1443。
- 女性对VQW-765应答比较P=0.034。
- VQW-765血浆浓度中间50%分位者SUDS改善比较P=0.033。
- 上述中间50%分位者的改善在女性亚组中P=0.005。
临床怎么用
- VQW-765作为α7-nAChR激动剂,可能为社交焦虑障碍的按需治疗提供新方向。
- 女性及达到中间50%血药浓度分位者可能更可能获益,但需进一步验证。
局限性
- 总体焦虑改善未达统计学显著,主要终点仅呈趋势。
- 显著改善仅限于女性亚组及特定血药浓度分位,需更大样本验证。
- 单次给药设计,长期疗效与安全性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the high prevalence of social and performance anxiety, current treatments do not meet the full needs of patients. Development of novel anxiolytics with rapid onset of action for on-demand treatment of social and performance anxiety is an active area of clinical research. AIMS: To examine the anxiolytic effect of VQW-765, an α7-nAChR agonist, in subjects with performance anxiety. METHOD: We conducted a randomised, double-blind, placebo-controlled trial of 230 adults with a history of public speaking anxiety. Participants were randomly assigned to receive a single oral dose of 10 mg VQW-765 (n = 116) or placebo (n = 114), followed by a Trier Social Stress Test (TSST). Anxiety levels were assessed by the Subjective Units of Distress Scale (SUDS). Heart rate was monitored during the TSST. Plasma concentration of VQW-765 was measured after the TSST. RESULTS: Subjects receiving VQW-765 showed a trend of improvement in intensity of anxiety, as measured by the SUDS, during the performance phase of a TSST compared with placebo (P = 0.1443). Females showed a larger magnitude and significant response to VQW-765 (P = 0.034). The pharmacokinetic/pharmacodynamic analysis observed an inverted U-shaped exposure-response relationship. Subjects in the middle 50% quantiles of VQW-765 plasma concentration showed significant improvement in the SUDS rating compared with placebo (P = 0.033); however, subgroup analysis revealed this was true only for females (P = 0.005). VQW-765 was safe and well tolerated. CONCLUSIONS: This is the first study showing anxiolytic effect of an α7-nAChR agonist in humans. VQW-765 is a promising candidate to be developed for on-demand treatment of social anxiety disorder.
引用
- He Y, Polymeropoulos CM, Mohrman MA, et al. Efficacy and safety of an alpha 7-nicotinic acetylcholine receptor agonist, VQW-765, in subjects with performance anxiety: randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2025. PMID: 40340771. doi:10.1192/bjp.2025.84
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。